Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia

被引：4
|
作者：
Trang, M. [1 ]
Hammel, J. P. [1 ]
Lakota, E. A. [1 ,3 ]
Safir, M. C. [1 ]
Bhavnani, S. M. [1 ]
Friedrich, L. [2 ,4 ]
Steenbergen, J. N. [2 ,5 ]
McGovern, P. C. [2 ,6 ]
Tzanis, E. [2 ,7 ]
Rubino, C. M. [1 ]
机构：
[1] Inst Clin Pharmacodynam Inc, Schenectady, NY 12305 USA
[2] Paratek Pharmaceut Inc, King Of Prussia, PA USA
[3] Vertex Pharmaceut Inc, Boston, MA USA
[4] AN2 Therapeut, Cambridge, MA USA
[5] Sci & Med Affairs Consulting LLC, Philadelphia, PA USA
[6] Venatorx Pharmaceut Inc, Malvern, PA USA
[7] Neurapt Therapeut, Philadelphia, PA USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2023年 / 67卷 / 01期
关键词：
omadacycline; pharmacokinetics; community-acquired bacterial pneumonia;
D O I：
10.1128/aac.02201-21
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Omadacycline for Community-Acquired Bacterial Pneumonia
    Stets, Roman
    Popescu, Monica
    Gonong, Joven R.
    Mitha, Ismail
    Nseir, William
    Madej, Andrzej
    Kirsch, Courtney
    Das, Anita F.
    Garrity-Ryan, Lynne
    Steenbergen, Judith N.
    Manley, Amy
    Eckburg, Paul B.
    Tzanis, Evan
    McGovern, Paul C.
    Loh, Evan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (06): : 517 - 527
  • [2] Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia
    Torres, Antoni
    Garrity-Ryan, Lynne
    Kirsch, Courtney
    Steenbergen, Judith N.
    Eckburg, Paul B.
    Das, Anita F.
    Curran, Marla
    Manley, Amy
    Tzanis, Evan
    McGovern, Paul C.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 104 : 501 - 509
  • [3] Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
    Leviton, Ira M.
    Amodio-Groton, Maria
    CLINICAL DRUG INVESTIGATION, 2022, 42 (03) : 193 - 197
  • [4] Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
    Ira M. Leviton
    Maria Amodio-Groton
    Clinical Drug Investigation, 2022, 42 : 193 - 197
  • [5] Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
    Lodise, Thomas P.
    Mistry, Rohit
    Young, Kate
    LaPensee, Kenneth
    CLINICAL DRUG INVESTIGATION, 2021, 41 (03) : 269 - 275
  • [6] Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
    Thomas P. Lodise
    Rohit Mistry
    Kate Young
    Kenneth LaPensee
    Clinical Drug Investigation, 2021, 41 : 269 - 275
  • [7] Correction to: Decision Analysis: Omadacycline Relative to Moxifoxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difcile Infection
    Thomas P. Lodise
    Rohit Mistry
    Kate Young
    Kenneth LaPensee
    Clinical Drug Investigation, 2021, 41 : 593 - 593
  • [8] Bacterial community-acquired pneumonia: risk factors for mortality and supportive therapies
    Lode, H.
    INTENSIVE CARE MEDICINE, 2009, 35 (03) : 391 - 393
  • [9] Bacterial community-acquired pneumonia: risk factors for mortality and supportive therapies
    H. Lode
    Intensive Care Medicine, 2009, 35
  • [10] Declining mortality among hospitalized patients with community-acquired pneumonia
    Simonetti, A. F.
    Garcia-Vidal, C.
    Viasus, D.
    Garcia-Somoza, D.
    Dorca, J.
    Gudiol, F.
    Carratala, J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (06) : 567.e1 - 567.e7
12345